Pro-Dex Q1 EPS Boosted by Ascendiant Capital Markets

Pro-Dex, Inc. (NASDAQ:PDEX) – Equities researchers at Ascendiant Capital Markets upped their Q1 2027 earnings estimates for Pro-Dex in a report issued on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now forecasts that the medical instruments supplier will post earnings per share of $0.67 for the quarter, up from their prior forecast of $0.66. Ascendiant Capital Markets currently has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Pro-Dex’s current full-year earnings is $2.78 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex’s Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.82 EPS, FY2027 earnings at $3.09 EPS, Q1 2028 earnings at $0.77 EPS, Q2 2028 earnings at $0.81 EPS, Q3 2028 earnings at $0.86 EPS, Q4 2028 earnings at $0.91 EPS and FY2028 earnings at $3.36 EPS.

Pro-Dex (NASDAQ:PDEX) last released its earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.20. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%.

Several other research analysts have also issued reports on the stock. Zacks Research upgraded shares of Pro-Dex to a “hold” rating in a research report on Tuesday, May 19th. Wall Street Zen upgraded Pro-Dex from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Finally, Weiss Ratings raised shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, September 4th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $74.00.

Pro-Dex Trading Up 0.5%

Shares of PDEX stock opened at $66.91 on Wednesday. Pro-Dex has a fifty-two week low of $23.47 and a fifty-two week high of $77.00. The company has a quick ratio of 2.45, a current ratio of 4.10 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $62.68 and a 200 day simple moving average of $58.18. The stock has a market capitalization of $214.31 million, a P/E ratio of 16.20 and a beta of 0.06.

Insider Activity at Pro-Dex

In other news, CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the transaction, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at approximately $1,340,631. This trade represents a 9.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of Pro-Dex stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the sale, the chief executive officer directly owned 79,228 shares in the company, valued at $4,702,974.08. The trade was a 0.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,300 shares of company stock valued at $1,351,657 over the last three months. 45.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Dempsey Capital Management LLC raised its holdings in shares of Pro-Dex by 6.2% in the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock valued at $286,000 after buying an additional 339 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its stake in Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock valued at $3,032,000 after acquiring an additional 1,735 shares during the last quarter. Navellier & Associates Inc. acquired a new stake in shares of Pro-Dex during the second quarter worth $322,000. Corsair Capital Management L.P. acquired a new position in shares of Pro-Dex during the 1st quarter worth about $532,000. Finally, Bank of New York Mellon Corp acquired a new position in Pro-Dex during the second quarter valued at approximately $678,000. 15.28% of the stock is owned by institutional investors.

Pro-Dex News Roundup

Here are the key news stories impacting Pro-Dex this week:

• Positive Sentiment: Ascendiant raises long-term earnings forecasts: Ascendiant Capital Markets lifted its FY2027 EPS estimate to $3.09 from $2.78 and maintained a “Buy” rating with a $74 price target. The firm projects EPS of $3.36 for FY2028, with quarterly estimates ranging from $0.77 to $0.91. The higher forecasts suggest expectations for continued profit growth at the medical-instruments supplier. Ascendiant Capital Markets analyst coverage
• Positive Sentiment: Several near-term estimates were increased: Ascendiant raised its Q1 2027 EPS forecast to $0.67 from $0.66, Q2 2027 to $0.72 from $0.69, and Q3 2027 to $0.82 from $0.74. These upward revisions provide a potential catalyst for the stock by indicating improving expectations for upcoming results.
• Positive Sentiment: Recent results exceeded expectations: Pro-Dex’s latest quarterly report showed $0.87 in EPS versus the $0.67 consensus estimate and revenue of $20.40 million versus estimates of $19.20 million. The company also reported a 17.62% net margin and 25.13% return on equity, reinforcing the bullish earnings narrative.
• Positive Sentiment: Institutional interest increased: Several funds initiated or expanded positions, including Bank of New York Mellon, Corsair Capital Management, Navellier & Associates, and California State Teachers’ Retirement System. Institutional investors collectively own approximately 15.28% of PDEX shares.
• Negative Sentiment: CEO disclosed a stock sale: CEO Kirk Richard Lee Van, Jr. sold 765 shares for approximately $45,410 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced his holdings by less than 1%, limiting its significance, but insider selling can be a modest sentiment headwind. Pro-Dex CEO stock sale

About Pro-Dex

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.

Based in Irvine, California, Pro-Dex serves customers in the United States and international markets.